论文部分内容阅读
目的：观察尿激酶新疗法治疗急性脑梗死临床疗效。方法：随机采用1对1配对照方法对30例急性脑梗死病人，设观察组与对照组。观察组应用尿激酶50万u加入生理盐水100ml，静滴，1次／日，连用3天，而后20万u加入生理盐水100ml静滴，三次／日，连用5天，最后口服肠溶阿斯匹林片0．1g，1次/日，一组均给予脱水，改善微循环等综合药物治疗，治疗一月后两组进行神经功能缺损评分对比，及治疗前后凝血四项比较，疗效评定。结果：治疗一月后观察组神经功能缺损评分及凝血四项，疗效评定与对照组比较有显著差异。结论：尿激酶新疗法治疗急性脑梗死尤于对照组，是一种有效治疗方法。
Objective: To observe the clinical effect of new urokinase therapy on acute cerebral infarction. Methods: A randomized one-to-one matching method for 30 patients with acute cerebral infarction, observation group and control group. Observation group of urokinase 500 000 u was added to 100 ml of normal saline, intravenous infusion, 1 time / day, once every 3 days, then 200000 u added saline 100ml intravenous infusion, three times / day, once every 5 days, 1 tablet / day, each group was given dehydration, improve microcirculation and other comprehensive medical treatment, treatment of neurological deficit score comparison of two groups after January, and the comparison of the four before and after treatment of coagulation, curative effect evaluation. Results: One month after treatment, the neurological deficit scores and coagulation scores in the observation group were significantly different from those in the control group. Conclusion: The new therapy of urokinase is more effective than the control group in the treatment of acute cerebral infarction.